Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information
DescriptionCorporate venture capital



2180 Sand Hill Road
Suite 460
Menlo Park, CA, 94025


President & Chief Executive Officer
Associate Investment Director
Associate Investment Director
Senior Investment Director
Investment Director
Investment Director


Astellas Venture Management

Astellas Venture Management is a financial organisation which targets its investments in the biotechnologies.

They invest in companies that are dedicated to developing new pharmaceutical seeds, or constructing a new drug discovery platform. Their investments are not limited to any geographical location.

Recent Milestones


Company Date Round Size Participants
Crescendo Biologics 4/2014Series A£2M4
Crescendo Biologics 12/2013Series A£17.5M3
Effector Therapeutics 5/2013Venture Round$45M7
DecImmune Therapeutics 2/2013Private Equity$2.25M3
Bicycle Therapeutics 12/2012Venture Round£3.75M5
F2G 9/2012Venture Round$30M6
PhaseBio Pharmaceuticals 6/2012Series B$23M5
Cleave Biosciences 10/2011Series A$44M6
Verastem 7/2011Series B$32M6
Fate Therapeutics 5/2011Series B$36M6
DecImmune Therapeutics 9/2010Venture Round$3.2M3
Nereus Pharmaceuticals 6/2010Series E$20M7
Epizyme 10/2009Series B$32M5
Viamet Pharmaceuticals 7/2009Series B$25M6
Intradigm Corporation 1/2009Series B$21.4M8
F2G 8/2008Venture Round£6.3M4
Inimex Pharmaceuticals 6/2008Series B$22M8
Lectus Therapeutics 2/2006Series A£8.2M4



  1. Crescendo Biologics Raises Further £2M in Series A Financing ( [edit]
  2. Crescendo Biologics Raises £17.5M in Series A Financing ( [edit]
  3. Effector Therapeutics snags $45M venture round from A-list backers ( [edit]
  4. DecImmune Therapeutics Completes $2.25M Equity Financing ( [edit]
  5. Bicycle Therapeutics Raises £3.75M in Funding ( [edit]
  6. F2G Ltd Completes $30 Million Financing Round to Fund Pre-clinical and Clinical Development of Novel Anti-fungal Compounds ( [edit]
  7. PhaseBio Pharmaceuticals Books $23M in Third Tranche of Series B ( [edit]
  8. Cleave Biosciences Raises $42M in Series A Financing ( [edit]
  9. Verastem rounds up $32M in second funding ( [edit]
  10. SEC ( [edit]
  11. DecImmune Therapeutics Receives $1M in Equity Financing; $2.2M Phase II SBIR Funding ( [edit]
  12. Nereus Pharmaceuticals, Inc.: Series E $20M ( [edit]
  13. Epizyme pulls in $32M in VC capital, new investors ( [edit]
  14. SEC ( [edit]
  15. Intradigm Corporation Closes Final Tranche of $21.4 Million Series B Financing; Philip Haworth, Ph.D. Appointed Chief Executive ( [edit]
  16. F2G Ltd completes £6.3million financing round to fund pre-clinical and clinical development ( [edit]
  17. Capital Funding Report [edit]
  18. Lectus Therapeutics closes Series A funding round raising £8.2 million ( [edit]
Edit This Page
Last Edited 4/15/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy